Suppr超能文献

利用抗AT1和AT2受体抗体识别血管紧张素II受体的组织和亚型特异性调节。

Recognition of tissue- and subtype-specific modulation of angiotensin II receptors using antibodies against AT1 and AT2 receptors.

作者信息

Rakugi H, Okamura A, Kamide K, Ohishi M, Sasamura H, Morishita R, Higaki J, Ogihara T

机构信息

Department of Geriatric Medicine, Osaka University Medical School, Japan.

出版信息

Hypertens Res. 1997 Mar;20(1):51-5. doi: 10.1291/hypres.20.51.

Abstract

Polyclonal antibodies have been prepared against synthetic peptides of human angiotensin II type-1 (AT1) and type-2 (AT2) receptors. Synthetic peptides corresponded to amino acids 15-24 of AT1 receptor and amino acids 241-253 of AT2 receptor. Western blot analysis of membranes from cell homogenates of COS-7 cells transfected with expression plasmids for mouse AT1b receptor, human vascular smooth muscle cells, and rat peripheral tissue demonstrated a major band of MW 44,000 with AT1 receptor antibody. Cell homogenates of COS-7 cells transfected with expression plasmids for human AT2 receptor showed a band of MW 44,000 with AT2 receptor antibody. Tissue homogenate of rat adrenal medulla and human pheochromocytoma presented a major band of MW 52,000 and a minor band of MW 44,000 with AT2 receptor antibody. AT1 receptor expression was in the following order: rat aorta > > lung, kidney, spleen, adrenal cortex > adrenal medulla, heart. Expression of AT2 receptor was in the following order: rat adrenal medulla > cortex, kidney, heart. Three-day treatment with CS866, an AT1 receptor antagonist, and temocapril, an angiotensin-converting enzyme inhibitor, suppressed AT1 receptor expression in the rat adrenal cortex, but not in the heart or adrenal medulla. AT2 expression was not affected by treatment with these drugs. These results suggest that newly developed antibodies for AT1 and AT2 receptors are useful in elucidating the regulation of subtype-specific receptor expression, and that AT1 but not AT2 receptors in adrenal tissue are regulated by angiotensin II.

摘要

已制备出针对人血管紧张素 II 1 型(AT1)和 2 型(AT2)受体合成肽的多克隆抗体。合成肽对应于 AT1 受体的第 15 - 24 位氨基酸和 AT2 受体的第 241 - 253 位氨基酸。对用小鼠 AT1b 受体表达质粒转染的 COS - 7 细胞、人血管平滑肌细胞和大鼠外周组织的细胞匀浆膜进行蛋白质免疫印迹分析显示,AT1 受体抗体出现一条分子量为 44,000 的主要条带。用人类 AT2 受体表达质粒转染的 COS - 7 细胞的细胞匀浆显示,AT2 受体抗体出现一条分子量为 44,000 的条带。大鼠肾上腺髓质和人嗜铬细胞瘤的组织匀浆用 AT2 受体抗体检测时出现一条分子量为 52,000 的主要条带和一条分子量为 44,000 的次要条带。AT1 受体表达顺序如下:大鼠主动脉 >> 肺、肾、脾、肾上腺皮质 > 肾上腺髓质、心脏。AT2 受体表达顺序如下:大鼠肾上腺髓质 > 皮质、肾、心脏。用 AT1 受体拮抗剂 CS866 和血管紧张素转换酶抑制剂替莫卡普利进行为期三天的治疗,可抑制大鼠肾上腺皮质中 AT1 受体的表达,但对心脏或肾上腺髓质无影响。这些药物治疗对 AT2 表达无影响。这些结果表明,新开发的针对 AT1 和 AT2 受体的抗体有助于阐明亚型特异性受体表达的调控机制,并且肾上腺组织中的 AT1 受体而非 AT2 受体受血管紧张素 II 的调节。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验